$BNTX

Moderna and Merck's successful Phase 3 trial for a personalized mRNA melanoma vaccine has renewed optimism in cancer vaccine development. Experts hope this success will reduce public skepticism and attract more investment. The mRNA technology, previously used in COVID-19 vaccines, is seen as promising for cancer treatment, with potential applications in other cancers as well.

The US FDA approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine for adults 65+ and high-risk individuals 5-64. The approval is based on clinical, real-world, and manufacturing data. The vaccine targets the XFG variant and will be available in the US from autumn 2026.

BioNTech halted its BNT122-01 trial for colorectal cancer due to survival imbalance. Moderna and Merck recently reported positive melanoma trial results. BioNTech's IMcode003 trial for pancreatic cancer showed 90% survival rate in responders, per Memorial Sloan Kettering.

BioNTech terminated a Phase 2 trial of its mRNA cancer vaccine, autogene cevumeran, for colorectal cancer after a DSMB found no likely efficacy improvement. The decision, made with Genentech, follows earlier futility concerns. No safety issues were identified. The pancreatic cancer trial of the same drug will continue. BioNTech plans to analyze the data and share findings later.

The FDA approved updated COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Sanofi for high-risk adults, including older individuals and those with underlying health conditions. The vaccines target current coronavirus variants and are expected to be available soon. However, federal recommendations on who should receive the shots remain unclear due to legal issues, potentially affecting availability in some states. Medical experts emphasize the vaccines' effectiveness in preventing severe illne

BioNTech halted its Phase 2 trial (BNT122-01) for mRNA cancer vaccine autogene cevumeran due to a mortality signal. The independent safety board found an imbalance in overall survival between treatment and control groups, recommending termination. The trial had 327 patients with high-risk colorectal cancer. BioNTech accepted the recommendation, but details on mortality rates were not disclosed.

BioNTech (BNTX) halted a Phase 2 colorectal-cancer trial with Roche's Genentech, citing an overall-survival imbalance. The stock, at $103.39, trades 25.79% above its GF Value estimate of $82.19. The pancreatic-cancer program continues, but the setback impacts the company's mRNA vaccine platform narrative.

BioNTech (BNTX) stock fell 8.3% after terminating a Phase 2 cancer trial due to survival imbalance. The setback follows recent optimism in the neoantigen vaccine space and raises concerns about its oncology pipeline. The FDA's anticipated COVID-19 vaccine approval did not offset investor worries.

BioNTech SE (BNTX) shares fell 10% after terminating a Phase 2 mRNA cancer vaccine trial for colorectal cancer due to futility. The setback contrasts with Moderna's recent success in melanoma, highlighting different outcomes in cancer types. BioNTech has €16.6B in cash and securities, and other trials remain ongoing. Investors await further data at ESMO Congress in October 2026.

BioNTech SE (BNTX) shares dropped 10% after terminating a Phase 2 cancer trial due to efficacy concerns. The trial, testing autogene cevumeran for colorectal cancer, was halted based on a DSMB recommendation. No safety issues were found. The company plans to analyze the data and share insights. Other trials, like IMcode003 for pancreatic cancer, continue. According to BioNTech, the decision was made after the futility boundary was crossed in October 2025.